US · Healthcare · Biotechnology
EPS came in at -0.87 against a street estimate of -0.53 — a miss of 64.2%.
Analysts rate Mirum Pharmaceuticals Inc a strong buy (14 buy, 0 hold, 0 sell out of 14) with an average price target of $153.43.
MIXED Strong Q2 commercial performance ($176M, +37% YoY) drives FY26 guidance raise to $680–700M. FDA requested Phase 3 for volixibat PSC despite robust VISTAS data; NDA filing delayed to H1 2027. FOP launch and pipeline readouts on track. Q2 2026 International markets expanding reimbursement. European zilurgisertib filing submitted. Analysts pressed FDA rationale for Phase 3 despite strong VISTAS data and precedent; management attributed to new team unfamiliarity, outlined iterative dialogue and possible supplementation. PBC VANTAGE discussed as potential regulatory reinforcement if needed. 2026-08-05…
Full summary in the app.
| Fund | Stake |
|---|---|
| Frazier Life Sciences Management, L.P. | 11.83% |
| Jupiter Topco LLC | 9.10% |
| BlackRock Inc | 6.76% |
| FMR Inc | 5.65% |
| T. Rowe Price Associates, Inc. | 4.09% |
| Vanguard Portfolio Management, LLC | 3.66% |
| Vanguard Capital Management, LLC | 3.47% |
| State Street Corp | 3.34% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Q3 2026 product sales were $185,721 thousand, up from $133,010 thousand in Q3 2025. • Nine-month 2026 product sales were $521,846 | 2026-11-03 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 net product sales were $185.7 million, up from $133.0 million in Q3 2025. • 2026 net product sales guidance was increased | 2026-11-03 |
| Company announcement · Q4 2026 HEADLINE NUMBERS • Mirum reported positive results from Cohort 2 of the pivotal PROGRESS study of ATEBRIOZ™ (zilurgisertib) in children aged 6 to <12 | 2026-10-26 |
| Company announcement · Q4 2026 HEADLINE NUMBERS • Mirum Pharmaceuticals announced topline Phase 3 EXPAND results for LIVMARLI (maralixibat) in patients aged 6 months or older with | 2026-10-13 |
| Company announcement · Q3 2026 HEADLINE NUMBERS • FDA approved Atebrioz™ (zilurgisertib) for adults and children aged 12 years and older with fibrodysplasia ossificans progressiva | 2026-09-28 |
| Board / officer change · Q3 2026 MIRUM PHARMACEUTICALS, INC. - FORM 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • Chief Medical Officer Leadership Change: Board of Directors appointed | 2026-09-08 |
| Quarterly report · Q2 2026 MIRUM PHARMACEUTICALS, INC. — FORM 10-Q SUMMARY For Quarterly Period Ended June 30, 2026 --- HEADLINE NUMBERS • Product Sales (6 months ended June | 2026-08-05 |
| Results announced · Q3 2026 MIRUM PHARMACEUTICALS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 net product sales: $176.2 million (vs. $127.8 million in Q2 2025, | 2026-08-05 |
Readable in the app.
| Announcement | Date |
|---|---|
| FDA approval of Atebrioz for fibrodysplasia ossificans progressiva treatment Mirum Pharmaceuticals announced two major regulatory wins in late September 2026. First, the FDA approved Atebrioz (zilurgisertib), a once-daily pill for fibrodysplasia ossificans progressiv | 2026-09-28 |
| Company completes merger and closes private placement offerings Mirum Pharmaceuticals completed a merger (consummated in January 2026) and simultaneously closed two private placement offerings that were previously announced in December 2025. Following th | 2026-01-26 |
| Company enters merger agreement and private placement subscription agreement AT&T announced it is acquiring worldwide rights to brelovitug, an investigational monoclonal antibody treatment for chronic hepatitis D virus (HDV) and hepatitis B virus (HBV), through a mer | 2025-12-08 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Mirum Pharmaceuticals Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.